University of Health Sciences and Pharmacy in St Louis selects new president to replace John Pieper bizjournals.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from bizjournals.com Daily Mail and Mail on Sunday newspapers.
Share this article
Share this article
ST. LOUIS, Feb. 24, 2021 /PRNewswire/ The University of Health Sciences and Pharmacy in St. Louis Board of Trustees has marked an important moment in the University s history with the announcement of its fifth president. David D. Allen, R.Ph., Ph.D., FASHP, FNAP, FAPhA, will serve as the University s next president, with his tenure beginning on July 1, 2021. Throughout my career, St. Louis College of Pharmacy, now UHSP, has always stood out as one of the premier private pharmacy institutions, and I could not be more honored or excited to lead this community, Allen shared. The road ahead of us is paved in opportunity, and I know that, together, we can build on the University s strong history and work toward achieving our full potential.
A paramedic wearing protective gear takes a nose-swab sample to be tested for the coronavirus in Karachi. Reuters/File
ISLAMABAD: As Pakistan continues to see a fall in Covid-19 cases, a website has placed the country on the 29th position in the list of 30 countries that have conducted the most number of tests per million population (PMP).
The National Command and Operation Centre (NCOC) has, meanwhile, recorded 1,050 patients who contracted the virus and 41 deaths over the last 24 hours.
Also, Pakistan is going to hold the first international conference dedicated to Covid-19 vaccine in which principal investigating officers of various vaccines will share their research papers.
LUMHS, UHS to collaborate on training, research tribune.com.pk - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tribune.com.pk Daily Mail and Mail on Sunday newspapers.
Drap okays marketing of CanSinoBIO vaccine
Top Story
February 18, 2021
ISLAMABAD: The Drug Regulatory Authority of Pakistan (DRAP) has granted ‘Emergency Use Approval’ to the CanSinoBIO Recombinant COVID-19 Vaccine Adenovirus Type 5 Vector (the “Ad5-nCoV”) and its marketing through private and public sectors. The approval has been granted following the communication of the results of the interim analysis of the global phase-III clinical trial of Ad5-nCoV to the Health Ministry by the Independent Data Monitoring Committee (IDMC).
The “Ad5-nCoV” has successfully met its pre-specified primary safety and efficacy criteria in the interim analysis.
There were no vaccine-related serious adverse events (SAEs) and, therefore, CanSinoBIO has been allowed by IDMC to continue to advance the global phase-III clinical trial of the Ad5-nCoV.